Metabolic Response to Infliximab in Pediatric Ulcerative Colitis

Exclusion Criteria

• •Female subjects who are pregnant, nursing, or planning pregnancy.
• •Concomitant diagnosis or history of congestive heart failure.
• •Serious infection in the 3 months prior to enrollment.
• •History of prior or current active or latent tuberculosis.
• •Immune deficiency syndrome, including documented human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
• •History of systemic lupus erythematosus.
• •A transplanted organ.
• •Known malignancy or history of malignancy within 5 years of enrollment.
• •History of demyelinating disease.
• •History of substance abuse.
• •History of diabetes mellitus.
• •Poor tolerability of venipuncture or lack of venous access during the study period.
• •A live virus vaccination within 3 months of enrollment.
• •Prior history of infliximab infusion or any other therapeutic agent targeted at reducing tumor necrosis factor-alpha (TNF-alpha).
• •Hypersensitivity to any murine proteins or other component of the product.
• •Inability to comply with study procedures